---

PUC Pharmacology - Dr. Sampurnanand Medical College, Jodhpur

Complete Model Answers (KD Tripathi Reference)

---

Q2. Classifying Drugs Used in Tuberculosis. Discuss Mechanism of Action, ADR & Uses of Rifampicin (20 marks)

Classification of Anti-TB Drugs

A. Based on Activity (KD Tripathi Classification)

B. Based on Bactericidal vs Bacteriostatic

C. Based on Site of Action

---

Rifampicin - Detailed

Mechanism of Action

• Bactericidal for both intracellular and extracellular organisms
• Active against rapidly multiplying AND intermittently dividing (sterilizing activity) bacilli
• Clinical significance: It sterilizes lesions and prevents relapse - key rationale for using it throughout treatment

Spectrum

Pharmacokinetics (clinically important)

• Oral, well absorbed, hepatic metabolism (induces its own metabolism - autoinduction)
• Biliary excretion, entero-hepatic circulation
• Colors body fluids orange-red (urine, tears, sweat, saliva) - must warn patient

ADR of Rifampicin (important for exam)

1. Hepatotoxicity - most important; transient rise in transaminases; fulminant hepatitis with INH combination - monitor LFT
2. GI disturbances - nausea, vomiting, abdominal pain
3. Orange-red discoloration of all body secretions (harmless; warn patient; stains contact lenses)
4. "Flu syndrome" - fever, chills, myalgia, headache - seen with intermittent high-dose regimens
5. Thrombocytopenic purpura, hemolytic anemia - immunological, with intermittent use
6. Renal failure (rare) - with intermittent therapy
7. Drug interactions - most important ADR in clinical practice:
   • Enzyme inducer (CYP450) - reduces efficacy of OCP (unwanted pregnancy), warfarin, corticosteroids, oral hypoglycemics, digoxin, ketoconazole, HIV antiretrovirals
   • Clinical pearl: Always counsel female patients on OCP about this interaction

Uses of Rifampicin

1. Tuberculosis - backbone of all RNTCP/NTEP regimens (HRZE x 2 months, then HR x 4 months)
2. Leprosy - multibacillary (MDT), paucibacillary regimen
3. MRSA - in combination only (resistance develops rapidly if used alone)
4. Meningococcal meningitis prophylaxis - rifampicin 600 mg BD x 2 days in contacts
5. H. influenzae type b prophylaxis - in household contacts
6. Brucellosis - with doxycycline
7. Legionella - with erythromycin

---

Q3. Short Notes (Any Four) - 4 x 5 = 20 marks

A. Indications & ADR of Insulin

Indications (Clinical)

1. Type 1 DM - absolute indication (beta cells destroyed)
2. Type 2 DM - when oral drugs fail, or acute illness, or HbA1c > 9% at diagnosis
3. Gestational diabetes - oral hypoglycemics contraindicated; insulin is drug of choice
4. Diabetic ketoacidosis (DKA) - IV regular insulin
5. Hyperosmolar Hyperglycemic State (HHS) - IV insulin
6. Perioperative management of diabetes
7. Critically ill patients - ICU glycemic control
8. Hyperkalemia - glucose + insulin drives K+ into cells (emergency)
9. Diabetic nephropathy with impaired renal function (safest OHA-free option)
10. Hepatic disease with DM

ADR of Insulin (KD Tripathi)

---

B. Superinfection

Mechanism

• Antibiotic suppresses normal flora (resident commensals)
• Ecological niche is occupied by resistant organisms or fungi
• These then overgrow and cause secondary infection

Organisms causing superinfection

Clinical Manifestations

• Oral thrush - white plaques (Candida)
• Vaginal candidiasis - after antibiotics in women
• Pseudomembranous colitis - C. difficile - watery/bloody diarrhea, treat with metronidazole or vancomycin (oral)
• Fungal septicemia in immunocompromised

Prevention

• Use narrow-spectrum antibiotics when possible
• Limit duration of therapy
• Prophylactic antifungal (fluconazole) in prolonged use
• Probiotics may help restore flora

---

C. Fixed Dose Combination (FDC)

Rationale/Advantages

1. Improved compliance - one pill instead of multiple
2. Convenience - fewer tablets
3. Pharmacokinetic synergy - drugs with similar half-lives given together
4. Prevention of resistance - cannot take one drug alone (anti-TB, HIV)
5. Cost-effective
6. Synergistic efficacy - e.g., amoxicillin + clavulanate

Disadvantages

1. Cannot adjust individual drug dose if patient has adverse effects
2. Bioavailability issues - one drug may alter absorption of another
3. If one drug not needed, patient still receives it
4. Dose adjustment difficult in renal/hepatic impairment
5. Risk of more ADR

Important Clinical Examples

Regulatory Note (India)

---

D. Uses of Progesterone

Physiological Role

• Prepares endometrium for implantation (secretory phase)
• Maintains pregnancy (corpus luteum, then placenta)
• Inhibits myometrial contractility
• Stimulates glandular development in breast

Pharmacological Uses (KD Tripathi)

ADR

• Weight gain, bloating
• Breakthrough bleeding
• Depression (some progestins)
• Androgenic effects (acne, hirsutism - with 19-nortestosterone derivatives)
• Virilization of female fetus (with androgenic progestins)

---

E. Common Properties of Aminoglycosides

Members (KD Tripathi)

Common Properties

• Bactericidal - concentration-dependent killing
• Bind irreversibly to 30S ribosomal subunit (specifically 16S rRNA)
• Cause misreading of mRNA → abnormal/nonfunctional proteins
• Disrupt cell membrane after initial binding
• Active against aerobic gram-negative bacilli; require oxygen for uptake (hence inactive against anaerobes)

• Aerobic gram-negative bacteria: E. coli, Klebsiella, Proteus, Pseudomonas, Serratia
• Gram-positive: Limited (mainly synergy with beta-lactams for endocarditis - Enterococcus, Viridans streptococci)
• Mycobacteria: Streptomycin (TB), Amikacin (MDR-TB)

• NOT absorbed orally (highly polar, ionized at body pH)
• Parenteral route (IV/IM) for systemic infections
• Does not cross BBB (poor CSF penetration)
• Excreted unchanged by kidneys (glomerular filtration)
• Once-daily dosing preferred (concentration-dependent + PAE)

• Enzymatic inactivation (acetyltransferases, adenylyltransferases, phosphotransferases) - most common
• Reduced uptake
• Ribosomal mutation

• • Loop diuretics (furosemide) → enhanced ototoxicity
• • NSAIDs → enhanced nephrotoxicity
• • Neuromuscular blockers → prolonged paralysis

• Gentamicin: gram-negative septicemia, endocarditis (synergy)
• Amikacin: MDR gram-negative, MDR-TB
• Streptomycin: TB, plague, brucellosis, tularemia
• Neomycin: topical, bowel sterilization before surgery

---

Q4. Drug Treatment of the Following (Any Four) - 4 x 5 = 20 marks

A. Typhoid Fever (Enteric Fever)

Drug of Choice (Current Guidelines + KD Tripathi)

Why not chloramphenicol anymore?

• Bone marrow suppression (aplastic anemia)
• High relapse rate
• Increasing resistance
• Ampicillin + Co-trimoxazole also used traditionally

Supportive treatment

• Antipyretics (paracetamol - avoid aspirin)
• Steroids (dexamethasone) in severe toxemia/encephalopathy
• No antidiarrheals

---

B. Thyroid Storm (Thyrotoxic Crisis)

Treatment (Sequential - KD Tripathi / Harrison approach)

• Propylthiouracil (PTU) 600-800 mg loading, then 200-250 mg 4-hourly
• PTU preferred over methimazole (also blocks T4→T3 conversion peripherally)

• Lugol's iodine (potassium iodide) - 8 drops every 6 hours
• Must give PTU first - otherwise iodine provides substrate for more hormone synthesis (Jod-Basedow effect)

• Propranolol 60-80 mg every 4-6 hours (oral) or IV 1-2 mg carefully
• Controls tachycardia, tremor, sweating (blocks peripheral T4→T3 conversion too)
• If bronchospasm: Diltiazem (CCB) as alternative

• IV fluids, cooling blankets for fever
• Paracetamol (NOT aspirin - displaces T4 from binding proteins)
• Treat precipitating cause (infection: antibiotics; stress ulcer: PPI)
• Dexamethasone 2 mg every 6 hours (blocks T4→T3 peripherally, prevents adrenal insufficiency)

---

C. Status Asthmaticus

Stepwise Management (KD Tripathi / GINA)

• High-flow O2 to maintain SpO2 94-98%

• Salbutamol (Albuterol) nebulization 2.5-5 mg every 20 minutes x 3, then hourly
• Mechanism: Gs → adenyl cyclase → cAMP → PKA → bronchial smooth muscle relaxation

• Add to salbutamol nebulization - additive bronchodilation
• 0.5 mg every 20 min x 3

• IV Hydrocortisone 200 mg stat, then 100 mg 6-hourly OR
• Oral Prednisolone 40-50 mg/day (equally effective if can swallow)
• Reduces airway inflammation, mucosal edema, reverses beta-2 receptor downregulation

• 2 g IV over 20 minutes if not improving
• Smooth muscle relaxation (Ca antagonism)
• Bronchodilator

• Loading dose: 5 mg/kg over 20-30 min (if not already on theophylline)
• Maintenance: 0.5-0.9 mg/kg/hr
• PDE inhibitor → increases cAMP → bronchodilation
• Narrow therapeutic index - monitor levels (10-20 mcg/mL)

---

D. MRSA Infection

• Resistance mechanism: Altered PBP-2a (mecA gene) - low affinity for all beta-lactams

Drug Treatment (KD Tripathi + Current Guidelines)

• 15-20 mg/kg IV every 8-12 hours
• Target trough: 15-20 mcg/mL (or AUC/MIC >400)
• Mechanism: Inhibits cell wall synthesis by binding D-Ala-D-Ala terminus (different target than penicillin)
• ADR: Red man syndrome (infusion-related), nephrotoxicity, ototoxicity
• Monitor renal function and trough levels

• 600 mg IV/oral BD
• MRSA pneumonia - some guidelines prefer over vancomycin
• Mechanism: Binds 23S rRNA (50S) - blocks initiation complex
• ADR: Myelosuppression (thrombocytopenia), serotonin syndrome (with SSRIs), peripheral neuropathy

• 4-6 mg/kg IV OD
• Depolarizes bacterial membrane (NOT for pneumonia - inactivated by surfactant)

• Rifampicin can be added to vancomycin/linezolid but NOT used alone
• TMP-SMX for community MRSA (SSTI - skin & soft tissue infections)
• Clindamycin for community MRSA skin infections if inducible resistance absent (D-zone test negative)

---

E. Methyl Alcohol (Methanol) Poisoning

• Formic acid causes metabolic acidosis and optic nerve damage (blindness)

Treatment

• IV access, fluids, monitor vitals

• 15 mg/kg IV loading, then 10 mg/kg every 12 hours
• Competitive inhibitor of alcohol dehydrogenase (ADH)
• Blocks conversion of methanol to toxic metabolites
• Preferred in children, pregnancy, liver disease

• 10% ethanol IV or 50% ethanol oral
• Mechanism: Higher affinity for ADH - competes with methanol, allowing methanol to be excreted unchanged by lungs/kidneys
• Target blood ethanol: 100-150 mg/dL
• Monitor carefully (CNS depression, hypoglycemia)

• Sodium bicarbonate IV - correct anion gap acidosis
• Target: pH >7.3

• Indications: Visual symptoms, severe acidosis (pH <7.1), serum methanol >50 mg/dL, renal failure
• Removes both methanol and formic acid directly

• 1 mg/kg IV every 4-6 hours
• Enhances formate metabolism (converts formate to CO2+H2O via folate pathway)
• Reduces optic nerve damage

• If visual symptoms: high-dose folinic acid + steroid (controversial)

---

Q5. Reasoning Questions - 5 x 3 = 15 marks

A. Why is Lidocaine used in Arrhythmias?

Mechanism

• Lidocaine is a Class IB antiarrhythmic (Na+ channel blocker)
• Blocks fast voltage-gated sodium channels - preferentially in ischemic/depolarized myocardium (use-dependent block)
• Shortens action potential duration (APD) and effective refractory period (ERP) in His-Purkinje and ventricular muscle
• Suppresses automaticity of ectopic foci - stops abnormal impulse generation
• Minimal effect on normal sinus node (hence no bradycardia in normal tissue)
• Does NOT affect AV node or atrial tissue significantly

Why preferred for ventricular arrhythmias specifically?

• It works best on tissues with rapid firing rates (ischemic cells fire rapidly)
• Does not affect QRS duration significantly (unlike Class IA drugs)
• IV formulation - rapid onset in emergency
• No hypotension (unlike quinidine)

Uses

• Acute VT/VF (especially post-MI)
• Lidocaine is no longer first-line (amiodarone has replaced it) but still used
• Also used in digitalis-induced arrhythmias

---

B. Why is Metoprolol used in Heart Failure?

Reasoning (KD Tripathi / Katzung)

• Failing heart triggers sympathetic activation → excess norepinephrine
• Chronic catecholamine excess causes:
  • Beta-1 receptor downregulation (desensitization)
  • Direct myocyte toxicity (apoptosis)
  • Increased heart rate → reduced diastolic filling
  • Remodeling (fibrosis, hypertrophy)

1. Upregulates beta-1 receptors - restores receptor sensitivity over time
2. Reduces heart rate - prolongs diastole, improves coronary perfusion
3. Prevents ventricular remodeling - reduces maladaptive hypertrophy/fibrosis
4. Anti-ischemic - reduces myocardial oxygen demand
5. Anti-arrhythmic - reduces risk of sudden cardiac death (SCD) - major benefit
6. Inhibits RAAS activation - sympatholysis reduces renin release

Clinical Evidence

• MERIT-HF trial: Metoprolol succinate reduced mortality by 34% in HFrEF
• Must start at very low dose (metoprolol 12.5-25 mg OD) and uptitrate slowly
• Contraindicated in decompensated/acute HF (can precipitate pulmonary edema)
• Use only in stable chronic HF (EF <40%)

---

C. Why is Amoxicillin Combined with Clavulanic Acid?

Reasoning

• Many bacteria produce beta-lactamase enzymes (e.g., S. aureus, H. influenzae, E. coli, Klebsiella, Moraxella)
• Beta-lactamase hydrolyzes the beta-lactam ring of amoxicillin → drug inactivated → treatment failure

• Clavulanate is a suicide inhibitor (irreversible inhibitor) of beta-lactamase
• It has a beta-lactam ring and binds irreversibly to beta-lactamase, inactivating it permanently
• By itself, clavulanate has negligible antibacterial activity
• But combined with amoxicillin: clavulanate destroys the beta-lactamase → amoxicillin is protected → can now kill bacteria

Clinical advantages

• Extended spectrum - covers beta-lactamase producing organisms
• Amoxicillin-clavulanate (Augmentin) covers: S. aureus (MSSA), H. influenzae, E. coli, Klebsiella, Moraxella, anaerobes (Bacteroides)
• Used for: LRTI, URTI, otitis media, sinusitis, UTI, bite wounds, SSTI, dental infections, Intra-abdominal infections

Other examples of beta-lactamase inhibitor combinations

• Piperacillin + Tazobactam (for hospital infections, Pseudomonas)
• Ampicillin + Sulbactam
• Ceftazidime + Avibactam (for carbapenem-resistant organisms)

---

D. Why is Bromocriptine used for Hyperprolactinemia?

Reasoning

• Dopamine (from hypothalamus) tonically inhibits prolactin secretion from lactotrophs of anterior pituitary
• Dopamine acts on D2 receptors on lactotrophs → inhibits prolactin release

• Deficiency of dopamine (or dopamine pathway blockade by antipsychotics)
• OR a prolactinoma (pituitary adenoma secreting excess prolactin)
• Excess prolactin → amenorrhea, galactorrhea, infertility, reduced libido, osteoporosis

• Bromocriptine is a D2 receptor agonist
• Mimics dopamine → acts on pituitary lactotrophs → inhibits prolactin synthesis and secretion
• Also causes tumor shrinkage in prolactinomas (reduces cell size and secretion)

Clinical Uses

• Prolactinoma (micro and macro) - Drug of choice; shrinks tumor in >80%
• Drug-induced hyperprolactinemia (antipsychotics, metoclopramide)
• Amenorrhea-galactorrhea syndrome
• Female infertility due to hyperprolactinemia
• Acromegaly - bromocriptine paradoxically reduces GH in some patients
• Parkinson's disease - D2 agonist activity (cabergoline now preferred)

ADR of bromocriptine

• Nausea, vomiting (most common - give with food)
• Postural hypotension
• Digital vasospasm (Raynaud's)
• Cabergoline preferred now (once/twice weekly, better tolerated, longer acting)

---

E. Why is Neostigmine Routinely Used After Pancuronium Administration in Operation?

Reasoning

• Competitive antagonist at nicotinic ACh receptors (NMJ)
• Blocks ACh from binding → prevents end-plate depolarization → skeletal muscle paralysis (surgical relaxation)
• After surgery ends, muscle paralysis must be reversed for the patient to breathe independently

• Pancuronium has long duration of action (~60-100 minutes)
• Residual neuromuscular blockade post-op = respiratory failure, aspiration risk, hypoxia
• Cannot safely extubate without confirming full reversal (4:4 TOF ratio ≥0.9)

• Neostigmine is an anticholinesterase (reversible inhibitor of acetylcholinesterase)
• Prevents breakdown of ACh at NMJ
• ACh accumulates → overcomes the competitive block of pancuronium (mass action)
• Restores NMJ transmission → muscle contraction returns → patient can breathe

• Neostigmine also increases ACh at muscarinic receptors (heart, lungs, gut)
• Causes: bradycardia, bronchospasm, excessive secretions, gut hypermotility
• Glycopyrrolate or Atropine (muscarinic antagonist) blocks these unwanted muscarinic effects
• Standard: Neostigmine 0.05 mg/kg + Glycopyrrolate 0.01 mg/kg (or Atropine 0.02 mg/kg) IV

• Sugammadex - Modified gamma-cyclodextrin that encapsulates rocuronium/vecuronium molecules → chemical reversal without neostigmine's muscarinic effects (preferred now in modern anesthesia)

---

Q6. Short Notes (5 x 3 = 15 marks)

A. ADR of Tetracyclines

Members

ADR (organized by system)

• Nausea, vomiting, epigastric pain, diarrhea
• Irritation if taken without water - esophageal ulceration (sit upright after dose)
• Superinfection - Candida (oral/vaginal thrush), C. difficile colitis

• Chelates Ca2+ → deposits in bones and teeth → yellow-brown discoloration of teeth (permanent), enamel hypoplasia
• Retards bone growth in children
• CONTRAINDICATED in children <8 years and pregnant women

• Demeclocycline > Doxycycline > Tetracycline
• Skin becomes hypersensitive to UV - phototoxic skin rash
• Advise sunscreen/avoid sunlight

• Fatty liver, hepatic necrosis (especially high IV doses, pregnancy)
• Avoid in hepatic disease

• Anti-anabolic effect - increases BUN (protein catabolism)
• Avoid in renal failure (doxycycline is safest in renal impairment among class)
• Outdated tetracycline → Fanconi syndrome (proximal tubular damage)

• Minocycline specifically causes dizziness, vertigo, ataxia

• Headache, papilledema - rare

• Milk, antacids, iron preparations → chelation → reduced absorption (take 1-2 hours apart)
• Warfarin - reduces gut flora → less Vit K → enhanced anticoagulation

---

B. Uses of Nitrates

Mechanism of Action

• Converted to nitric oxide (NO) in vascular smooth muscle
• NO activates guanylyl cyclase → increases cGMP → activates PKG → dephosphorylation of myosin light chain → vasodilation
• Predominantly venodilators (reduce preload) at low doses
• Arteriolar dilation at higher doses (reduces afterload)

Preparations

Clinical Uses

• Stable angina: GTN SL for acute attacks (terminate attack); long-acting nitrates for prophylaxis
• Unstable angina: IV nitroglycerine
• Vasospastic (Prinzmetal's) angina: Nitrates + Calcium channel blockers
• Mechanism: Reduces preload (↓ venous return → ↓ LVEDP → ↓ ventricular wall tension → ↓ O2 demand); Also dilates coronary arteries

• IV nitroglycerin reduces pain, limits infarct size
• Reduces preload and afterload → reduces myocardial O2 demand

• IV/SL nitrate - rapidly reduces preload → reduces pulmonary capillary wedge pressure → relieves breathlessness

• Isosorbide dinitrate + Hydralazine combination (A-HeFT trial) in patients intolerant to ACE inhibitors (especially in Black patients)

• GTN SL relaxes esophageal smooth muscle

• Isosorbide dinitrate (along with CCBs)

• IV nitroglycerin or sodium nitroprusside

Nitrate tolerance and how to prevent it

• Nitrate tolerance = loss of efficacy with continuous use; due to depletion of sulfhydryl (-SH) groups needed for NO generation
• Prevention: Nitrate-free interval of 8-12 hours (usually overnight)
• Eccentric dosing of ISMN (8 AM and 2 PM, not 12-hourly)

Contraindications

• Phosphodiesterase-5 inhibitors (Sildenafil, Tadalafil) - severe hypotension (ABSOLUTE CI - exam favorite)
• Right ventricular infarction - do NOT use (preload reduction dangerous)
• Hypertrophic obstructive cardiomyopathy (HOCM)
• Severe aortic stenosis

---

C. Prevention of Resistance in Antimicrobial Therapy

Why resistance develops

• Natural selection of mutant strains under antibiotic pressure
• Horizontal gene transfer (plasmids, transposons)
• Misuse/overuse of antibiotics

Mechanisms of Resistance (brief)

• Beta-lactamase production (destroys drug)
• Altered PBPs (MRSA - mecA gene)
• Efflux pumps (removes drug from cell)
• Reduced permeability (altered porins)
• Ribosomal modification (macrolide resistance)
• Target modification (fluoroquinolone - DNA gyrase mutation)

Prevention Strategies (KD Tripathi - High Yield)

• Prescribe only when bacterial infection is proven/strongly suspected
• Avoid antibiotics for viral URTI, cough, cold
• Culture and sensitivity before starting (or blood cultures before broad-spectrum)

• Use narrow-spectrum antibiotics whenever possible
• Do not use broad-spectrum antibiotics as first line for simple infections
• De-escalate to targeted therapy once C&S results available

• Subtherapeutic doses allow resistant mutants to survive
• Complete the full course of antibiotics
• However, shorter courses (3-day UTI, 5-day CAP) are now supported where evidence exists

• Prevents emergence of resistant mutants (each drug suppresses mutants resistant to the other)
• Anti-TB DOTS: HRZE prevents resistance
• HIV: triple antiretroviral therapy (HAART)
• Prevents single-step mutation conferring resistance to both drugs

• Topical antibiotics promote resistance; prefer antiseptics where possible

• Surgical prophylaxis: single pre-operative dose only (not prolonged post-op)
• Appropriate choice, dose, and timing (30-60 min before incision)

• Hand hygiene, isolation of MRSA/resistant organism patients
• Disinfection of surfaces, proper biomedical waste disposal
• HEPA filters, negative pressure rooms for TB

• Prevents infections → reduces antibiotic use → reduces selection pressure
• Pneumococcal, Hib, meningococcal, typhoid vaccines

• Veterinary overuse drives resistance that crosses to humans (One Health approach)

---

D. Artemisinin-Based Combination Therapy (ACT)

Background

• Artemisinin (Qinghaosu) derived from Chinese herb Artemisia annua
• Fastest-acting antimalarial - reduces parasite biomass rapidly

Mechanism of Action

• Artemisinin contains an endoperoxide bridge
• Activated by heme (in infected red cells) → generates reactive oxygen species (ROS) and free radicals
• Free radicals alkylate parasite proteins → damage parasite membranes, mitochondria, hemoglobin digestion enzymes → parasite death
• Active against all asexual stages including gametocytes (reduces transmission)

Why Combination?

• Artemisinin derivatives have short half-life (1-2 hours for artesunate; 2-3 hours for artemether)
• Monotherapy would require 7-day course → poor compliance
• Risk of recrudescence with artemisinin alone
• Partner drug (long half-life) kills remaining parasites after artemisinin clears most of the burden
• Prevents emergence of resistance (two different mechanisms required for failure)

ACT Regimens Used in India (NVBDCP/WHO)

Artemisinin derivatives used

• Artesunate (water-soluble - IV for severe malaria, also oral)
• Artemether (oil-soluble - IM injection, also oral in AL combination)
• Dihydroartemisinin (DHA) (active metabolite of both)
• Arteether (IM)

ADR

• Generally well tolerated
• Neurotoxicity in animals (not clearly proven in humans at therapeutic doses)
• Embryotoxic (avoid in 1st trimester - but severe malaria in pregnancy: use IV artesunate, risk:benefit)
• Mild GI disturbances

Clinical Pearl (WHO 2022)

---

E. Beta-2 Receptors & Their Pharmacotherapeutic Importance

Beta-2 Receptor Characteristics

• G-protein coupled receptor (Gs protein)
• Activation → adenyl cyclase → increased cAMP → PKA activation → phosphorylation of target proteins
• Location: Bronchial smooth muscle (relaxation), uterine smooth muscle (relaxation), vascular smooth muscle in skeletal muscle (dilation), liver (glycogenolysis), mast cells (inhibits mediator release), heart (minor, beta-1 dominant)

Pharmacotherapeutic Uses of Beta-2 Agonists

• SABAs: First-line for acute symptom relief (bronchodilation within 5 min)
• LABAs: NEVER use as monotherapy (without ICS) - may mask worsening, risk fatal attack
• Inhaled route preferred - direct delivery, reduced systemic ADR

• Salbutamol, Ipratropium (SAMA) for relief
• Indacaterol (LABA), Salmeterol/Formoterol for maintenance

• Salbutamol IV, Terbutaline - relax uterine smooth muscle (beta-2 in myometrium)
• Delay delivery 24-48 hours to allow corticosteroids to mature fetal lungs
• Replaced by atosiban (oxytocin antagonist) in many centers (fewer CV ADR)

• Adrenaline (Epinephrine) - alpha + beta-1 + beta-2 agonist
• Beta-2 component: bronchodilation, mast cell stabilization

• IV salbutamol drives K+ into cells temporarily (via Na+/K+ ATPase activation)
• Used as emergency measure before dialysis

ADR of Beta-2 Agonists

• Tremor (skeletal muscle beta-2 stimulation) - most common with oral/systemic
• Tachycardia (some beta-1 spillover at high doses)
• Hypokalemia (K+ driven into cells - especially IV)
• Hyperglycemia (liver glycogenolysis)
• Tolerance with prolonged use (receptor downregulation)
• Paradoxical bronchospasm (rare, with excessive inhaler use)

Beta-2 in Disease Context (Clinical Exam Tip)

• Beta-2 agonists are BRONCHODILATORS - key in asthma + COPD
• Beta-blockers (non-selective like propranolol) are contraindicated in asthma - block beta-2 → bronchoconstriction; use cardioselective beta-1 blockers (metoprolol, atenolol) with caution if needed

---

Summary Quick Reference Table

---

---

PATHOLOGY PUC EXAM - Dr. SN Medical College, Jodhpur

Second MBBS | Batch 2024 | 13-07-2026

Complete Model Answers (Robbins & Kumar Reference)

---

Que. 2 - Clinical Case: 56-year-old male, 4-month fever (evening rise), night sweats, weight loss, hemoptysis; sputum positive; right upper lobe cavitation on CXR

a) Probable Diagnosis (3 marks)

Justification (Clinical Correlation)

---

b) Etiopathogenesis and Morphology of Right Lung (4 marks)

Etiopathogenesis of Secondary TB (Robbins Ch. 8)

• Primary TB: First infection in a non-sensitized individual; Ghon complex (subpleural focus + hilar lymph node)
• Secondary TB (Reactivation/Post-primary): Occurs in a previously sensitized person; endogenous reactivation of dormant bacilli (most common) or rarely re-infection

• BCG-vaccinated or previously infected person develops waning cellular immunity (e.g., elderly, HIV, diabetes, steroids, malnutrition)
• Dormant bacilli in Simon foci (apical/upper lobe) reactivate

• Macrophages engulf bacilli but cannot destroy them (M. tuberculosis resists phagolysosomal fusion - blocks phagosome acidification)
• CD4+ T cells (Th1) activated → secrete IFN-gamma
• IFN-gamma activates macrophages → form epithelioid granuloma
• TNF-alpha from macrophages → recruits more cells, systemic symptoms
• Central caseous necrosis occurs (cell-mediated immunity + bacilli toxins)

• Caseous material liquefies (proteolytic enzymes from activated macrophages)
• Liquefied material drains into bronchus → cavity formation
• Cavity = rich in O2, abundant bacilli → highly infectious sputum
• Erosion of Rasmussen's aneurysm (pulmonary artery within cavity) → hemoptysis

• Higher oxygen tension (TB is a strict aerobe)
• Less lymphatic drainage
• Less phagocytic activity

Morphology of Right Lung in Secondary TB (Gross + Microscopy)

• Right upper lobe: irregular cavity, 2-10 cm diameter
• Wall of cavity: thick, fibrous, shaggy, necrotic lining
• Yellow-white caseous (cheese-like) material
• Satellite lesions may be present
• Lower lobes may show endobronchial spread (patchy consolidation - "bronchopneumonia pattern")
• Pleural thickening over affected area

1. Central caseous necrosis - acellular, granular, eosinophilic, ghost cell outlines
2. Epithelioid macrophages - elongated nuclei, pink cytoplasm (activated macrophages)
3. Langhans' giant cells - up to 40+ nuclei arranged in horseshoe/peripheral pattern (pathognomonic)
4. Lymphocytic cuffing - peripheral ring of CD4+ and CD8+ T cells
5. Fibroblastic rim - peripheral fibrous wall (healing response)
6. AFB demonstrable within macrophages on ZN stain
7. Late stage: calcification (dystrophic calcification of caseous material)

---

c) Investigations to Aid Diagnosis (3 marks)

Microbiological

Radiological

Immunological

Histopathological

• Bronchoscopy with BAL (bronchoalveolar lavage) or transbronchial biopsy - if sputum negative
• Shows caseating granuloma with Langhans giant cells

Other Supportive Investigations

• CBC: Lymphocytosis, elevated ESR, mild anemia
• LFT: Baseline before ATT (hepatotoxic drugs)
• HIV testing: Mandatory (co-infection common)
• Blood glucose: Rule out diabetes (risk factor for TB)

---

Que. 3 - Explain Why (5 x 3 = 15 marks)

a) Vitamin B12 Deficiency Occurs After Ileal Resection

Normal B12 Absorption Pathway (Robbins Ch. - Anemias)

1. Dietary B12 (cobalamin) released from food in stomach by pepsin + HCl
2. Bound to R-binders (haptocorrins) in stomach
3. In duodenum: pancreatic proteases cleave R-binders
4. Free B12 binds Intrinsic Factor (IF) - secreted by gastric parietal cells
5. IF-B12 complex travels to terminal ileum (last 60-80 cm)
6. Specific receptors (Cubilin/AMN receptors) on ileal enterocytes bind IF-B12 complex
7. B12 is absorbed; IF is degraded within ileal cells
8. B12 enters portal circulation bound to Transcobalamin II (TCII)

Why ileal resection causes B12 deficiency:

• The only site of B12 absorption is the terminal ileum (IF-B12 receptor, cubilin)
• After ileal resection, this absorptive surface is lost
• IF-B12 complex cannot be absorbed anywhere else in the GI tract
• Dietary B12 passes through stool unabsorbed
• Body stores of B12 are large (~3-5 years) - so deficiency takes years to manifest
• Result: Megaloblastic anemia, subacute combined degeneration of spinal cord (SACD)

---

b) Kayser-Fleischer (KF) Rings in Wilson's Disease

Wilson's Disease Pathogenesis (Robbins - Liver chapter)

• Wilson's disease (Hepatolenticular Degeneration) - AR genetic disorder
• Mutation: ATP7B gene (chromosome 13) - codes for copper-transporting P-type ATPase
• ATP7B located in hepatocytes - responsible for:
  • Incorporation of copper into ceruloplasmin (for export)
  • Excretion of copper into bile for fecal elimination
• Defective ATP7B → copper cannot be exported into bile or bound to ceruloplasmin
• Copper accumulates progressively in liver, brain, cornea, kidneys

Why KF Rings Form (Robbins)

• Excess free copper is transported in blood (bound to albumin, free ionic copper)
• Copper deposits in Descemet's membrane of the cornea (peripheral zone, near limbus)
• Descemet's membrane is the posterior layer of corneal stroma (produced by corneal endothelium)
• Copper ions complex with corneal proteins → golden-brown/greenish-yellow pigmented ring at the periphery of the cornea (limbus)
• Seen at the junction of cornea and sclera in the upper and lower poles

Clinical Details

• Visible to naked eye in advanced disease
• Best seen on slit-lamp examination (required for subtle/early KF rings)
• Present in nearly 100% of Wilson's with neuropsychiatric disease
• Present in ~50-60% of patients with hepatic Wilson's
• Also seen in other cholestatic liver diseases (primary biliary cirrhosis) but less common
• Reversible with copper chelation therapy (D-penicillamine, trientine)

---

c) Crew-Cut Appearance of Skull X-ray in Beta-Thalassemia Major

Pathogenesis (Robbins - Red cell disorders)

• Beta-thalassemia major (Cooley's anemia): Mutations in beta-globin gene → absent/markedly reduced beta-globin chains
• Excess alpha-globin chains precipitate → form inclusion bodies → damage RBC membranes → severe hemolysis → profound anemia (Hb as low as 3-4 g/dL)
• Chronic severe anemia → massive compensatory erythropoietic hyperplasia in all hematopoietic sites

How Skull X-ray Shows "Crew Cut" / "Hair-on-End" Appearance

1. Bone marrow is the primary site of erythropoiesis
2. In response to severe hemolytic anemia, bone marrow undergoes massive expansion (up to 30-fold)
3. Diploic space (spongy bone between inner and outer tables of skull) expands massively to accommodate the hyperplastic marrow
4. The outer table of the skull is resorbed/thinned
5. The inner table remains intact
6. Expanding marrow creates perpendicular bony spicules (trabeculae) radiating outward through the thinned outer table
7. On skull X-ray: these spicules appear as short vertical streaks perpendicular to the inner table = "crew cut" or "hair on end" or "brush appearance"

---

d) Low Fibre Diet Predisposes to Colon Cancer

Dietary Fibre - Role in Normal Colonic Function

• Dietary fiber (insoluble: cellulose, hemicellulose; soluble: pectin, gum) increases stool bulk and accelerates intestinal transit
• Fibre is fermented by colonic bacteria → short-chain fatty acids (SCFA: butyrate, propionate, acetate)
• Butyrate is the primary energy source for colonocytes; has anti-proliferative and pro-apoptotic effects on colonocytes

How Low Fibre Diet Promotes Colon Cancer (Robbins - GI Tumors)

• Low fibre → reduced stool bulk → slow transit through colon
• Stool remains in contact with colonic mucosa for longer duration
• Prolonged exposure to fecal carcinogens (secondary bile acids, nitrosamines, heterocyclic amines)

• Low fibre → less stool bulk → carcinogens are not diluted
• Higher concentration of mutagenic substances in contact with mucosa

• Less fermentable substrate for colonic bacteria → less butyrate
• Butyrate normally: inhibits histone deacetylase → promotes differentiation and apoptosis of colonocytes
• Deficiency → loss of anti-tumor effect on mucosa

• High fat + low fibre diet → increased primary bile acids
• Colonic bacteria convert primary to secondary bile acids (deoxycholic acid, lithocholic acid) - these are promoters of carcinogenesis
• Low fibre → less binding and excretion of bile acids

• Low butyrate → reduced differentiation, increased cell turnover → more chances of mutational errors

• APC → beta-catenin → KRAS → SMAD4 → TP53 pathway (chromosomal instability pathway)
• Microsatellite instability pathway (Lynch syndrome - MLH1, MSH2 mutations)
• Carcinogens promote somatic mutations in these pathways

---

e) Cobweb Appearance in CSF of Tubercular Meningitis

Tubercular Meningitis Pathogenesis (Robbins - CNS infections)

• M. tuberculosis reaches meninges via hematogenous spread from primary focus
• Subependymal tubercles (Rich foci) form adjacent to subarachnoid space
• Rupture of Rich foci → bacilli enter CSF → exuberant exudate in basal cisterns and subarachnoid space

CSF Findings in TBM

Why Cobweb Clot Forms

• TBM produces very high protein content in CSF (due to breakdown of blood-brain barrier, meningeal exudate, tissue necrosis)
• Fibrinogen and fibrin are present in the exudate (along with globulins, albumin)
• On standing (within 30-60 minutes), the fibrinogen polymerizes and the delicate fibrin network precipitates
• This forms a thin, wispy, web-like clot on the surface - the "cobweb clot"
• Gross appearance: looks exactly like a spider's cobweb
• Cobweb = HIGH protein (fibrinogen) = characteristic of TBM

• Cobweb clot: pick it up on a platinum loop → smear → ZN stain - often reveals AFB (highest yield site in CSF)
• Other conditions with cobweb: Froin's syndrome (spinal block), some viral meningitis (much rarer)

---

Que. 4 - Short Notes (4 x 5 = 20 marks)

a) Complications of Myocardial Infarction

Complications (Early and Late)

• Mechanism: Ischemic injury to conduction system; re-entry circuits in peri-infarct zone
• Ventricular fibrillation - most common cause of death in first hour ("sudden cardiac death")
• Ventricular tachycardia, heart block, sinus bradycardia (inferior MI - vagal)
• Timing: First 24-48 hours most dangerous

• Occurs with loss of >40% of LV myocardium
• Reduced CO, hypotension, pulmonary edema
• 10-15% of patients; 80% mortality

• Mechanism: Neutrophil infiltration + collagenase activity → coagulative necrosis at maximum → weakest zone 3-5 days
• Types:
  • Free wall rupture (most common rupture): Cardiac tamponade → sudden death
  • Interventricular septum rupture (IVS): Acute VSD → left to right shunt → RV failure
  • Papillary muscle rupture: Acute mitral regurgitation → flash pulmonary edema

• Fibrinous pericarditis: 2-3 days post-MI (transmural infarction) - pleuritic chest pain, friction rub
• Dressler's Syndrome: 2-10 weeks post-MI; immune-mediated (anti-heart antibodies); fever, pericarditis, pleuritis, arthritis

• Endocardial damage over infarcted area → platelet aggregation, thrombus
• May embolize → stroke, mesenteric ischemia, limb ischemia
• Anterior MI (LV apex) - most common site

• Late complication (weeks to months)
• Infarcted wall replaced by fibrous scar → paradoxical bulging during systole
• Contains clot → systemic embolism
• Ventricular failure, arrhythmias

• Functional mitral regurgitation
• Most common post-infarction mechanical complication (excluding rupture)

• Complicates inferior/posterior MI (RCA territory)
• Raised JVP, hypotension, clear lungs (Triad)
• Nitrates CONTRAINDICATED (preload reduction → shock)

---

b) Oncogenes

Definition

Mechanisms of Proto-oncogene to Oncogene Conversion

Categories of Oncoproteins (Robbins)

• PDGF-B → overexpressed in astrocytomas
• TGF-alpha (normally EGF ligand) → overexpressed in many carcinomas

• HER2/neu (ERBB2) - amplified in breast (30%), treated with Trastuzumab
• EGFR (ERBB1) - mutated in lung adenocarcinoma
• BCR-ABL - t(9;22) → constitutively active tyrosine kinase → CML

• RAS family (KRAS, NRAS, HRAS) - G-protein; point mutation → cannot hydrolyze GTP → permanently "ON"
• Most commonly mutated oncogene in human cancers (colorectal, pancreatic, lung)

• MYC (c-MYC, N-MYC, L-MYC) - amplified/translocated → drives S-phase entry
• MYC translocation t(8;14) → Burkitt's lymphoma

• Cyclin D1 - amplified in breast, head & neck cancers → bypasses G1 checkpoint
• CDK4 - amplified in some sarcomas

• BCL-2 - translocation t(14;18) → overexpressed → inhibits apoptosis → follicular lymphoma
• "Hallmark of cancer: Resistance to apoptosis" (Hanahan & Weinberg)

• Targeted therapy - based on oncogene "addiction" concept
• Imatinib → BCR-ABL (CML)
• Trastuzumab → HER2/neu (Breast)
• Erlotinib/Gefitinib → EGFR (Lung)

---

c) H. Pylori Gastritis

H. Pylori - The Organism

• Helicobacter pylori: Gram-negative, spiral/curved rod, microaerophilic
• Produces urease, proteases, phospholipases, VacA (vacuolating cytotoxin), CagA (cytotoxin-associated gene A)
• Found in the mucus layer overlying gastric surface epithelium; specially adapted to survive gastric acidity

Pathogenesis

• Urease → splits urea → NH3 + CO2 → NH3 neutralizes acid locally → creates microenvironment

1. Adheres to gastric epithelial cells via BabA adhesin (binds Lewis B blood group antigen)
2. CagA protein injected into epithelial cells via Type IV secretion system → activates signaling → IL-8 release → neutrophil recruitment
3. VacA (vacuolating cytotoxin) → vacuolar degeneration of epithelial cells → apoptosis
4. Urease products (NH3) → direct cytotoxic injury to mucosa
5. Phospholipases → disrupt mucus layer → exposes epithelium to acid
6. Neutrophilic infiltration → active gastritis

Morphology (Histology - Robbins)

• Chronic active gastritis = key pattern
  • Neutrophils within gastric glands ("lymphoid follicles") - active component
  • Lymphocytes and plasma cells in lamina propria - chronic component
  • Lymphoid follicles with germinal centers in mucosa (characteristic of H. pylori)
  • Goblet cell intestinal metaplasia (precancerous lesion) in long-standing cases
  • Glandular atrophy

Diseases caused by H. pylori (Robbins)

Diagnosis

• Rapid Urease Test (CLO test) on endoscopic biopsy (fastest)
• Histology (Giemsa/Warthin-Starry silver stain visualizes organisms)
• Urea breath test (13C) - non-invasive, gold standard for confirmation of eradication
• Stool antigen test, Serology (ELISA - not for eradication confirmation)

Treatment (Triple therapy)

• Amoxicillin + Clarithromycin + PPI x 14 days (or Bismuth quadruple therapy)

---

d) Sickle Cell Anemia

Molecular Basis

• Autosomal recessive disorder
• Point mutation: Glutamic acid → Valine at position 6 of beta-globin chain (GAG → GTG)
• Produces HbS instead of HbA
• HbSS = Sickle cell disease; HbAS = Sickle cell trait (carrier; protected against P. falciparum malaria)

Pathogenesis of Sickling

1. On deoxygenation → HbS molecules polymerize → form rigid long fibers (tactoids)
2. Fibers distort the RBC → elongated sickle/crescent shape
3. Sickled cells are rigid and inflexible (cannot traverse capillaries)
4. Initially reversible (reoxygenation → unsickle), but repeated sickling → irreversibly sickled cells (ISC)

1. Hemolytic anemia (intravascular + extravascular)
   • ISC have decreased membrane deformability → destroyed by spleen
   • RBC lifespan reduced from 120 days to 10-20 days
   • Intravascular hemolysis → hemoglobinuria, jaundice
2. Vaso-occlusion (ischemic injury)
   • Sickled cells block small vessels → tissue ischemia/infarction
   • Enhanced adhesion of sickled cells to endothelium (via VCAM-1, P-selectin, thrombospondin)

Clinical Features

• Pallor, jaundice, splenomegaly (early; later autosplenectomy)
• Cholelithiasis (pigment stones from chronic hemolysis)

• Triggered by: infection, dehydration, cold, hypoxia, acidosis, alcohol
• Severe bone pain (marrow infarction) - most common presenting crisis
• Dactylitis (Hand-foot syndrome): In infants - swelling of hands/feet (infarction of small bones)
• Acute chest syndrome: Fever + chest pain + pulmonary infiltrates (vaso-occlusion + fat/marrow emboli in pulmonary vasculature) - leading cause of death
• Stroke: Young patient with sickle cell + stroke = hallmark
• Priapism (vaso-occlusion of corpus cavernosum)
• Autosplenectomy: Repeated infarction of spleen → fibrosis → functional asplenia → increased susceptibility to encapsulated organisms (S. pneumoniae, H. influenzae, Salmonella osteomyelitis)

Morphology (Robbins)

• Sickle/crescent-shaped RBCs
• Howell-Jolly bodies (nuclear remnants - asplenic)
• Target cells, polychromasia, reticulocytosis
• Nucleated RBCs

• Spleen: initially congested (sequestration crises) → later fibrotic, small, autosplenectomized
• Bone marrow: hyperplastic (compensatory erythropoiesis)
• Liver: congestion, fatty change
• Kidneys: papillary necrosis (medullary ischemia)

Investigations

• Peripheral smear (sickle cells + features above)
• Hb electrophoresis (gold standard): HbS (>80%), absent HbA, increased HbF
• Sickling test (sodium metabisulfite) - screening
• HPLC (gold standard in neonates)

Management (Key drugs)

• Hydroxyurea (increases HbF production - most important disease-modifying drug)
• Voxelotor, Crizanlizumab (newer agents)
• Folic acid supplementation
• Penicillin prophylaxis (asplenic patients)
• Pneumococcal + meningococcal vaccination
• Bone marrow transplant (curative)

---

Que. 5 - Short Notes (3 x 5 = 15 marks)

a) Differences Between Dry and Wet Gangrene

Special Types

• Gas gangrene (Clostridial myonecrosis): C. perfringens produces alpha-toxin (lecithinase) → liquefaction + gas formation → crepitus. Emergency.
• Fournier's gangrene: Wet gangrene of perineum/scrotum - polymicrobial; aggressive debridement mandatory.

---

b) Seminoma

Definition

• Most common testicular tumor (40-50% of all GCTs)
• Peak age: 30-40 years (slightly older than NSGCT)
• Highly radiosensitive and chemosensitive - best prognosis among GCTs

Etiopathogenesis (Robbins)

• Precursor lesion: Germ Cell Neoplasia In Situ (GCNIS) (formerly carcinoma in situ)
• Risk factors: Cryptorchidism (most important - 10x increased risk); Klinefelter's; family history; contralateral GCT
• Isochromosome 12p [i(12p)] - virtually pathognomonic chromosomal abnormality in all GCTs
• Increased copy number of genes on 12p (e.g., CCND2, NANOG, STELLA)

Gross Morphology (Robbins)

• Testis enlarged, may be massively so
• Cut section: Homogeneous, cream-colored/grayish-white lobulated mass (like a fish-flesh)
• No necrosis, no hemorrhage (distinguishes from NSGCT)
• Well-circumscribed, replaces testicular parenchyma
• Tunica albuginea rarely breached (unlike NSGCT)

Microscopy (Robbins - HIGH YIELD)

1. Sheets, cords, or lobules of large polygonal cells with clear/pale cytoplasm (rich in glycogen - PAS positive)
2. Large central nucleus with prominent 1-2 nucleoli
3. Lymphocytic infiltrate in stroma (T-cell mediated immunity - explains sensitivity to immune response)
4. Granulomatous reaction (epithelioid granulomas with Langhans-type giant cells) - in 20% cases
5. Delicate fibrovascular septa divide cells into lobules
6. Mitotic figures present

Immunohistochemistry

• PLAP positive (Placental Alkaline Phosphatase) - characteristic
• CD117 (c-KIT) positive
• OCT3/4 positive (stem cell marker)
• AFP negative (elevated AFP rules out pure seminoma - indicates non-seminomatous elements)
• hCG: 10-15% of seminomas have syncytiotrophoblastic giant cells → mild hCG elevation

Serum Tumor Markers

• AFP: Normal (if elevated → not pure seminoma)
• hCG: Mildly elevated in ~10% (syncytiotrophoblasts)
• LDH: Elevated (reflects tumor bulk)

Clinical Features

• Painless testicular enlargement (classic presentation)
• May present with metastases (retroperitoneal LN - paraaortic)
• Back pain if paraaortic nodes involved
• Gynecomastia if hCG-secreting syncytiotrophoblasts present

Spread

• Lymphatic: Para-aortic lymph nodes (retroperitoneal) - first site
• Hematogenous (late): Lungs, liver, brain, bones

Prognosis

• Excellent - 95%+ 5-year survival even with metastases
• Radiosensitive (for stage I-II retroperitoneal nodes)
• BEP chemotherapy (Bleomycin + Etoposide + Cisplatin) for advanced disease

---

c) Differences Between Lobar Pneumonia and Bronchopneumonia

Four Stages of Lobar Pneumonia (Robbins - HIGH YIELD)

---

Que. 6 - Short Notes (4 x 5 = 20 marks)

a) Composition of Health Care Team

Definition

Primary Health Care Team (PHC Level - India)

Hospital Level Team (Secondary / Tertiary)

• Doctors (specialists, residents, interns)
• Nurses (staff nurses, nursing supervisors)
• Paramedics (physiotherapists, OT technicians, radiographers, lab technicians)
• Administrative staff, social workers, dietitians, pharmacists

Interprofessional Team Care Principles

• Clear role definition; effective communication
• Shared decision-making
• Mutual respect; patient-centered focus

---

b) Hashimoto Thyroiditis

Definition

Epidemiology

• Most common in middle-aged women (F:M = 10-20:1)
• Strong genetic association: HLA-DR3, HLA-DR5; associated with other autoimmune diseases (type 1 DM, SLE, Sjögren's)

Pathogenesis (Robbins - Autoimmune Disorders)

1. CD4+ T cell (Th1) activation against thyroid peroxidase (TPO), thyroglobulin, TSH receptor
2. Th1 cells → IFN-gamma → macrophage activation → cytotoxic T cell (CD8+) killing of follicular cells
3. Anti-thyroid antibodies (by B cells):
   • Anti-TPO antibodies (most sensitive, >90%) - marker of Hashimoto's
   • Anti-thyroglobulin antibodies (less specific)
   • Anti-TSH receptor antibodies (blocking type - cause hypothyroidism)
4. Antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells
5. Apoptosis of follicular cells via FAS/FAS-L pathway

Morphology (Robbins)

• Symmetrically enlarged thyroid (goiter)
• Pale, firm, slightly nodular
• Capsule intact, non-adherent to surroundings

1. Diffuse lymphoplasmacytic infiltrate with germinal center formation (lymphoid follicles in thyroid - pathognomonic)
2. Hürthle cell (oxyphilic/oncocytic) metaplasia of follicular cells - large cells with abundant granular eosinophilic cytoplasm (mitochondria-rich) - characteristic
3. Follicles are small, atrophic, with scant colloid
4. Interstitial fibrosis (variable)
5. No capsular invasion

Clinical Features

• Initial phase: Transient thyrotoxicosis ("Hashitoxicosis") - due to follicular cell destruction releasing T3/T4
• Then: Hypothyroidism (gradual, over years) - most common end result
• Goiter (may be the presenting feature)
• Increased risk of Primary Thyroid Lymphoma (B-cell, marginal zone / MALT type - arises from lymphoid infiltrate)

Investigations

• Anti-TPO antibodies (most sensitive - positive in >90%)
• Anti-thyroglobulin antibodies
• TSH (elevated in hypothyroidism), Free T4 (low), Free T3 (low)
• FNAC: Hürthle cells + lymphocytes

Treatment

• Levothyroxine replacement for hypothyroidism

---

c) Fibroadenoma

Definition

Epidemiology

• Most common breast tumor in women under 35 years
• Peak incidence: 20-35 years

Pathogenesis

• Estrogen-sensitive (increases in size during pregnancy; regresses after menopause)
• Lobular units undergo hyperplastic overgrowth of both epithelium and stroma
• No premalignant potential (with exception of complex fibroadenoma variants)

Gross Morphology (Robbins)

• Well-circumscribed, encapsulated, mobile, firm-rubbery mass
• Round/oval, 1-10 cm (usually 2-3 cm)
• Cut section: Gray-white, with small slit-like clefts (from compressed ducts)
• Whorled appearance; may have calcification (older lesions - "popcorn calcification" on mammogram)
• Slips out of surrounding breast tissue like a marble (clinical exam - "breast mouse")

Microscopy (Robbins - HIGH YIELD)

• Loosely cellular, myxoid stroma with spindle fibroblasts
• Glandular spaces lined by two layers: inner luminal epithelial + outer myoepithelial cells
• No atypia, no pleomorphism
• No mitotic activity (benign)
• Stroma may calcify in older lesions

Clinical Features

• Painless, firm, mobile lump - moves freely ("breast mouse")
• Usually solitary; may be multiple (15-20%)
• No skin changes, no nipple discharge, no lymphadenopathy
• Grows slowly; may enlarge during pregnancy (estrogen effect)

Investigations

• Triple assessment: Clinical + Imaging (USG/Mammogram) + FNAC/biopsy
• USG: Well-defined, homogeneous, hypoechoic oval mass with posterior acoustic enhancement
• Mammogram: Oval dense shadow with popcorn calcification (if calcified)
• FNAC: Epithelial cell clusters + stroma + naked nuclei (myoepithelial)

Management

• Conservative (observe) if <3 cm and triple assessment benign
• Surgical excision if growing, >3-4 cm, or patient anxiety
• Giant fibroadenoma (>5 cm) - mandatory excision

Variants

• Juvenile fibroadenoma (adolescents - may be large)
• Complex fibroadenoma (cysts >3mm, sclerosing adenosis, epithelial calcifications - slightly increased breast cancer risk)
• Giant fibroadenoma (>5 cm, especially in African women, adolescents)
• Phyllodes tumor (cellular stroma, leaf-like projections - may be benign, borderline or malignant - NOT a fibroadenoma but arises from similar TDLU)

---

d) Nephrotic Syndrome

Definition (Robbins)

• Hypoalbuminemia (<3.5 g/dL)
• Generalized edema (anasarca)
• Hyperlipidemia and lipiduria

Pathogenesis (Robbins)

1. Fenestrated endothelium (charge barrier - anionic glycocalyx)
2. Glomerular Basement Membrane (GBM) (size + charge barrier)
3. Podocyte foot processes with slit diaphragm (Nephrin, Podocin, CD2AP, Alpha-Actinin-4)

• Immune/toxic injury → podocyte foot process effacement (fusion/simplification) → loss of slit diaphragm → massive protein leakage (mainly albumin)
• Loss of anionic charge on GBM → further protein loss

Causes (Robbins)

• Diabetes mellitus (diabetic nephropathy) - most common cause of NS in adults worldwide
• Systemic Lupus Erythematosus (SLE) - Class V (membranous) lupus nephritis
• Amyloidosis - Congo red positive; apple-green birefringence (AL or AA type)
• Drugs: NSAIDs (MCD), gold, penicillamine, heroin (FSGS)
• Infections: HBV (membranous), HCV (MPGN), malaria (quartan), HIV (FSGS - collapsing variant)
• Malignancy: Paraneoplastic - Hodgkin's lymphoma (MCD), solid tumors (membranous)
• Preeclampsia

Investigations

• 24-hour urine protein (>3.5 g/day) - confirmation
• Urine routine: Protein +++, lipid droplets, fatty casts (oval fat bodies, Maltese cross)
• Serum albumin (low), Serum cholesterol/TG (high)
• Renal function tests (creatinine, BUN)
• Renal biopsy - definitive diagnosis (LM + IF + EM)
• Anti-PLA2R antibody (membranous nephropathy)
• ANA, anti-dsDNA (lupus)
• HBsAg, HCV antibodies
• Blood glucose, HbA1c (diabetes)
• SPEP (monoclonal protein for amyloid)

Treatment Principles

• MCD: Prednisolone (first-line); excellent response; cyclophosphamide for relapse
• FSGS: Steroids + ACE inhibitors/ARBs (reduce proteinuria)
• Membranous: ACE inhibitor/ARB (conservative); immunosuppression (rituximab, cyclophosphamide + steroids) for high-risk
• Dietary: Low-salt, adequate protein; diuretics for edema

---

Quick Revision Summary Table

---